Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
Howard C MargoleseMatthieu BoucherFrancois TherrienGuerline ClerziusPublished in: BMC psychiatry (2022)
ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated.